Last reviewed · How we verify
NaCl (C)
Sodium chloride (saline) restores electrolyte balance and fluid volume by providing essential sodium and chloride ions to the body.
Sodium chloride (saline) restores electrolyte balance and fluid volume by providing essential sodium and chloride ions to the body. Used for Fluid and electrolyte replacement in dehydration, Hypovolemia and shock management, Perioperative fluid maintenance.
At a glance
| Generic name | NaCl (C) |
|---|---|
| Sponsor | Oslo University Hospital |
| Drug class | Electrolyte replacement / Inorganic salt |
| Modality | Small molecule |
| Therapeutic area | General/Supportive Care |
| Phase | FDA-approved |
Mechanism of action
NaCl is an inorganic salt that serves as a fundamental electrolyte replacement therapy. It maintains osmotic pressure, supports nerve and muscle function, and restores intravascular volume in cases of dehydration, hypovolemia, or electrolyte depletion. Saline solutions are isotonic or hypertonic depending on concentration and clinical need.
Approved indications
- Fluid and electrolyte replacement in dehydration
- Hypovolemia and shock management
- Perioperative fluid maintenance
- Electrolyte imbalance correction
Common side effects
- Hypernatremia (with hypertonic solutions)
- Fluid overload / pulmonary edema (with excessive administration)
- Hyperchloremic acidosis
- Phlebitis (at IV site)
Key clinical trials
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer (PHASE3)
- A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma (PHASE2, PHASE3)
- Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies (PHASE1)
- Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial (PHASE2)
- Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer (PHASE2, PHASE3)
- Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma (PHASE2)
- Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NaCl (C) CI brief — competitive landscape report
- NaCl (C) updates RSS · CI watch RSS
- Oslo University Hospital portfolio CI